Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7180240

Cc1cccc(C)c1C(=O)Pc1ccccc1-c1ccccc1.[Li]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 1/20 0.39
▸ FABP3 P05413 1/20 0.39
▸ FABP4 P15090 1/20 0.39
▸ MCL1 Q07820 1/20 0.38
▸ NR1H4 Q96RI1 1/20 0.37
▸ FFAR1 O14842 4/20 0.37
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ HNF4A P41235 1/20 0.37
▸ FFAR4 Q5NUL3 2/20 0.36
▸ FGFR1 P11362 1/20 0.36
▸ FGFR2 P21802 1/20 0.36
▸ FGFR4 P22455 1/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180235 0.97 MYC (0.39) MYCFABP3FABP4MCL1NR1H4
Lithium SCHEMBL7179768 0.90 FABP3 (0.46) MYCFABP3FABP4KMT2AMEN1
Lithium SCHEMBL7174791 0.88 LMNA (0.40) MCL1FFAR1FFAR4KMT2AMEN1
SCHEMBL7179761 0.87 FABP3 (0.46) MYCFABP3FABP4KMT2AMEN1
SCHEMBL7174785 0.85 LMNA (0.40) MCL1FFAR1FFAR4KMT2AMEN1
Lithium SCHEMBL7175218 0.84 RXRB (0.38) MCL1PDCD1CD274KMT2AMEN1
Lithium SCHEMBL7188994 0.83 L3MBTL1 (0.36) MYCFABP3FABP4KMT2ASMN1; SMN2
Lithium SCHEMBL7188166 0.83 CYP2A6 (0.46) FABP3FABP4HNF4AKMT2AMEN1
Lithium SCHEMBL7189343 0.82 KMT2A (0.35) MCL1PDCD1CD274KMT2AMEN1
SCHEMBL7175212 0.81 RXRB (0.38) MCL1PDCD1CD274KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MYC 3413/4885FABP3 3252/4885FABP4 4550/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MYC 3031/4885FABP3 2807/4885FABP4 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.